O-RAN-ALLIANCE-E.V.
18.2.2021 23:38:13 CET | Business Wire | Press release
As of January 2021, the O-RAN ALLIANCE welcomes LG U+ as its 28th operator member. With strong support by its expanding number of contributors, the alliance now counts more than 260 companies from around the globe, building a foundation and unifying the Radio Access Networks (RAN) industry towards open, intelligent, virtualized and fully interoperable RAN solutions.
O-RAN Open Summit (Virtual) Complements the O-RAN Demos at MWC Shanghai 2021
For latest updates on the evolution of open RAN, the O-RAN ALLIANCE invites interested industry participants to the O-RAN Open Summit . This compact virtual event will open with operator executives delivering a summary of O-RAN’s progress and developments. Subsequent keynotes and panel discussions with major O-RAN players will summarize the achievements and next steps in the O-RAN specification effort, testing and integration, and delivery of open software for the RAN.
The O-RAN Open Summit virtual event is scheduled for February 25, 2021 from 9:00-11:00pm China Standard Time (8:00-10:00am EST, 14:00-16:00 CET). For more information and to join the summit free of charge, please visit our website .
O-RAN Demonstrations at MWC Shanghai 2021 and at the O-RAN Virtual Showcase
Two O-RAN demonstrations are planned to be presented at the MWC Shanghai 2021:
- Sageran is demonstrating a complete O-RAN white-box small cell solution based on an x86 platform with an FPGA Accelerator card that showcases a stand-alone end-to-end use case using white box hardware for an indoor cell which supports MIMO with 4T4R. The demo is hosted at MWC Shanghai 2021 by Sageran, booth N2.C114 , as well as at the O-RAN Virtual Exhibition .
- VIAVI and Rohde & Schwarz are jointly demonstrating validation of open fronthaul performance. As network operators adopt disaggregated, multi-vendor networks, rigorous testing of performance and interoperability must accompany conformance testing. This demo showcases generation and delivery of typical standards based testcase IQ data to the O-RU utilizing the Lower Layer Split Option 7.2x fronthaul interface with the VIAVI TM500 O-RU Tester. Moreover, uplink and downlink fronthaul logs are captured, and RF signal generation and capture are performed using the Rohde & Schwarz VSG and VSA hardware with VSE Software for RF and IQ signal analysis. Testcase workflow is simplified for the end user utilizing the VIAVI O-RU Test Manager, providing a single point of test control. The demo is hosted at MWC Shanghai 2021 by VIAVI Solutions, booth N1.B137 , as well as at the O-RAN Virtual Exhibition .
5 more virtual demos for MWC Shanghai 2021 have enriched the O-RAN Virtual Exhibition :
- ITRI is demonstrating traffic steering xApps and Near-Real-Time Radio Intelligent Controller platform utilizing E2 procedures to monitor cell and UE metrics generated by RAN simulator and to offload some UE to neighbor cells such that the A1 policy is guaranteed.
- NVIDIA and VMWare are jointly demonstrating PoC of Aerial 5G gNB Layer-1 orchestration on VMWare telco cloud platform. This demo showcases NVIDIA Aerial SDK as cloud native function, with docker containers and Kubernetes manifests. Aerial cuBB onboarded to VMWare telco cloud platform offers service agility, operational efficiency and reduced CAPEX/OPEX through MANO.
- Viettel is demonstrating an end-to-end-solution based on Intel server (Xeon-D) with NIC (XXV710-DA2T) that is integrated with an outdoor micro O-RU via an Open Fronthaul Interface. The base station connects with EPC and Viettel’s eNB perform a complete NSA (Option 3X) white-box base station solution and ready for Commercial Deployment. The integrated system is verified using a commercial UE through the attach and speed test.
- Altiostar has teamed up with Airtel and NEC to demonstrate interoperability testing and integration of massive MIMO radio units (O-RU) and virtualized distributed units (O-DU) running on commercial-off-the-shelf (COTS) servers. The demonstration features a commercial end-to-end Open Fronthaul interface based on O-RAN specifications.
- Parallel Wireless is demonstrating 2G, 3G, 4G and 5G O-RAN based macro Open RAN to expand and modernize cellular networks with reduced TCO & simplified maintenance. It’s been proven in rural in 50+ networks globally and is now scalable for urban 2G 3G 4G while unleashing the full 5G potential.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 260 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations. For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218006088/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom